Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.
Hodgkin Disease
DRUG: Bortezomib|DRUG: Dexamethasone
Overall response rate (complete and partial responses)
Toxicity|Event free survival|Overall survival|Duration of response|Treatment administration (dose-intensity, total dose)
The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.